One of the central themes of this discussion has been that additional clinical trials in heterogeneous populations of critically-ill patients are unlikely to yield useful results. Instead, using clinical and/or biologic factors to identify more homogeneous subgroups of critically-ill patients for investigation may be a more fruitful approach (doi: 10.1164/rccm.201604-0697ED).
To date, there remains no specific therapy for patients with sepsis. How will the Sepsis III definitions help facilitate a more nuanced approach to sepsis clinical trial design? What do you think are the next steps towards precision medicine in sepsis?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.